These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11417447)

  • 1. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment.
    Schumacher S; Abbasi I; Weise D; Hatorp V; Sattler K; Sieber J; Hasslacher C
    Eur J Clin Pharmacol; 2001 May; 57(2):147-52. PubMed ID: 11417447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR
    Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of repaglinide in subjects with renal impairment.
    Marbury TC; Ruckle JL; Hatorp V; Andersen MP; Nielsen KK; Huang WC; Strange P
    Clin Pharmacol Ther; 2000 Jan; 67(1):7-15. PubMed ID: 10668848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics and pharmacodynamics of repaglinide.
    Hatorp V
    Clin Pharmacokinet; 2002; 41(7):471-83. PubMed ID: 12083976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
    Damsbo P; Clauson P; Marbury TC; Windfeld K
    Diabetes Care; 1999 May; 22(5):789-94. PubMed ID: 10332683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
    Owens DR; Luzio SD; Ismail I; Bayer T
    Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes.
    Hatorp V; Huang WC; Strange P
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1475-8. PubMed ID: 10199798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing.
    van Heiningen PN; Hatorp V; Kramer Nielsen K; Hansen KT; van Lier JJ; De Merbel NC; Oosterhuis B; Jonkman JH
    Eur J Clin Pharmacol; 1999 Sep; 55(7):521-5. PubMed ID: 10501822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.
    Strange P; Schwartz SL; Graf RJ; Polvino W; Weston I; Marbury TC; Huang WC; Goldberg RB
    Diabetes Technol Ther; 1999; 1(3):247-56. PubMed ID: 11475269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
    Culy CR; Jarvis B
    Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function.
    Hasslacher C;
    Diabetes Care; 2003 Mar; 26(3):886-91. PubMed ID: 12610054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
    Nattrass M; Lauritzen T
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide.
    Balfour JA; Faulds D
    Drugs Aging; 1998 Aug; 13(2):173-80. PubMed ID: 9739505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repaglinide pharmacokinetics in healthy young adult and elderly subjects.
    Hatorp V; Huang WC; Strange P
    Clin Ther; 1999 Apr; 21(4):702-10. PubMed ID: 10363735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes.
    Landgraf R; Frank M; Bauer C; Dieken ML
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S38-44. PubMed ID: 11063283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology and clinical experience with repaglinide.
    Massi-Benedetti M; Damsbo P
    Expert Opin Investig Drugs; 2000 Apr; 9(4):885-98. PubMed ID: 11060717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.
    Damsbo P; Marbury TC; Hatorp V; Clauson P; Müller PG
    Diabetes Res Clin Pract; 1999 Aug; 45(1):31-9. PubMed ID: 10499883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
    Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
    Br J Clin Pharmacol; 2008 Dec; 66(6):818-25. PubMed ID: 18823304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repaglinide: prandial glucose regulation in clinical practice.
    Owens DR; McDougall A
    Diabetes Obes Metab; 2000 Mar; 2 Suppl 1():S43-8. PubMed ID: 11225759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.